

**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1.- 10. (Cancelled).

11. (Original) An inhalable solid pharmaceutical formulation comprising (a) an active ingredient substance susceptible to chemical interaction with a carrier, (b) a carrier and (c) calcium stearate.

12. (Currently Amended) An inhalable solid pharmaceutical formulation as claimed in claim 11 ~~further comprising one or more of the features described in any one or more of claims 3 to 10 wherein the carrier is a reducing sugar.~~

13. (Currently Amended) An inhalable solid pharmaceutical formulation as claimed in claim ~~23 11 or claim 12~~ wherein the active ingredient substance is 3-(4-{{6-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl)amino}hexyl} oxy}butyl) benzenesulfonamide; or a salt, solvate or physiologically acceptable derivative thereof, and the carrier is lactose.

14. (Original) A method of reducing or inhibiting chemical interaction between an active ingredient substance and a carrier susceptible to chemical interaction, which comprises mixing calcium stearate with said active ingredient substance and said carrier.

15. (Original) A method of inhibiting chemical degradation of an active ingredient substance in a formulation comprising a carrier and an active ingredient substance, which method comprises mixing calcium stearate with said active ingredient substance and said carrier.

16. (Currently Amended) A method as claimed in claim 14 or 15 further comprising one or more of the features described in any one or more of claims 3 to 10 wherein the carrier is a reducing sugar.

17. (Cancelled).

18. (Currently Amended) A method for treating asthma, chronic obstructive pulmonary disease (COPD), chronic or wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, or rhinitis, comprising administering to a patient in need thereof an inhalable solid pharmaceutical formulation as claimed in any of claims 11 to 13.

19. (Original) A method of preparing a solid pharmaceutical preparation comprising combining in one or more steps: (a) an active ingredient substance susceptible to interaction with a carrier, (b) a carrier and (c) calcium stearate.

20. (New) An inhalable solid pharmaceutical formulation as claimed in claim 12, wherein the carrier is lactose.

21. (New) An inhalable solid pharmaceutical formulation as claimed in claim 11, wherein the calcium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.

22. (New) An inhalable solid pharmaceutical formulation as claimed in claim 11, wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

23. (New) An inhalable solid pharmaceutical formulation as claimed in claim 11, wherein said drug substance is selected from:

3-(4-{{(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino}hexyl) oxy}butyl) benzenesulfonamide;  
3-(3-{{[7-((2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl}-amino}heptyl}oxy}propyl)benzenesulfonamide;

4-<{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and  
4-<{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,  
or a salt, solvate or physiologically acceptable derivative thereof.

24. (New) A method as claimed in claim 15, wherein the carrier is lactose.

25. (New) A method as claimed in claim 14, wherein the calcium stearate is present in an amount of from 0.1 to 20% w/w based on the total weight of the composition.

26. (New) A method as claimed in claim 14, wherein the active ingredient substance is present in an amount of from 0.01% to 50% w/w based on the total weight of the composition.

27. (New) A method as claimed in claim 14, wherein said drug substance is selected from:

3-(4-<{[6-<{(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino]hexyl}oxy}butyl) benzenesulfonamide;  
3-(3-<{[7-<{(2*R*)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl}amino]heptyl}oxy}propyl)benzenesulfonamide;  
4-<{(1*R*)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol and  
4-<{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol,  
or a salt, solvate or physiologically acceptable derivative thereof.

28. (New) A method as claimed in claim 14, wherein the active ingredient substance is 3-(4-<{[6-<{(2*R*)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino]hexyl}oxy}butyl); or a salt, solvate or physiologically acceptable derivative thereof, and the carrier is lactose.